Medicinova Inc (MNOV) - News Archive

Unveiling Hope: MediciNova s Milestone in ALS Treatment Through COMBAT-ALS TrialAmyotrophic Lateral Sclerosis (ALS) remains one of the most formidable challenges in neurology today. Characterized by the degeneration of...

The landscape of drug development in neurodegenerative diseases is continually evolving, marked by innovative approaches such as the Expanded Access Program (EAP). This article analyzes the recent enrollment of the firs...

: MediciNova, Inc. a biopharmaceutical firm listed on both NASDAQ and the Tokyo Stock Exchange, has shared an update regarding its ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) for treating Amyotrophic Lateral...

This article presents a overview of MediciNova Inc’s recent corporate progress outlined by CEO Yuichi Iwaki, amidst its financial performance in the evolving therapeutic landscape for Amyotrophic Lateral Sclerosis (ALS)...

In a noteworthy turn of events for MediciNova, Inc. a biopharmaceutical company based in La Jolla, California, the firm has received notification regarding monetary damages stemming from a patent settlement involving Sa...

MediciNova’s MN-166 (Ibudilast) in ALS and Glioblastoma: Expansion, Recognition, and Promising Data MediciNova, Inc. a biopharmaceutical company, continues to advance its investigational drug MN-166 (ibudilast) in multi...

In a significant development for the treatment of Amyotrophic Lateral Sclerosis (ALS), MediciNova, Inc. has achieved a milestone with the acceptance of an abstract for a poster presentation concerning its investigationa...

MN-166 (Ibudilast) in Advanced Clinical Trials for ALS: Promising Developments at the 2024 NEALS Annual Meeting Amyotrophic Lateral Sclerosis (ALS) continues to pose significant challenges due to its devastating, progre...

MediciNova s David H. Crean, Ph.D. Drives Investor Engagement and Public Relations, Reinforcing Company s Future DirectionIn a strategic move to enhance communication with stakeholders, MediciNova, a clinical-stage biop...

MediciNova, a biopharmaceutical company, recently announced new data and findings from a Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma (GBM) patients at the American Society of Clinical Oncology (ASCO...

MediciNova, Inc., a leading biopharmaceutical company, has recently made significant strides in the field of cardiometabolic conditions and acute lung injuries. Through two poster presentations at the 92nd European Athe...

In a recent development, MediciNova, a biopharmaceutical company at the forefront of medical innovation, has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application. Thi...

MediciNova, a soaring juggernaut in the biopharmaceutical industry traded on both the renowned NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), has made a trium...

MediciNova, a leading biopharmaceutical company traded on NASDAQ (MNOV) and the Tokyo Stock Exchange (Code Number: 4875), is proud to announce that two abstracts showcasing the potential of their experimental drugs, MN-...

MediciNova, a biopharmaceutical company, recently presented new data and results from a nonclinical study evaluating MN-166 (ibudilast) in a model of chlorine gas-induced acute lung injury (CIALI). The study, presented...